Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of furosemide injection in China. Welcome to wholesale bulk high quality furosemide injection for sale here from our factory. Good service and reasonable price are available.
Furosemide Injection is a potent diuretic that belongs to the Loop Diuretics category. It exerts a diuretic effect by inhibiting the reabsorption of sodium, chloride, and potassium by the thick segment of the ascending branch of the renal medullary loop, increasing the excretion of these electrolytes in urine. This substance quickly enters the bloodstream through intravenous or intramuscular injection, avoiding the first pass effect of oral administration. After injection, the drug rapidly distributes to various tissues throughout the body, especially the kidneys. Furosemide is metabolized less in the liver and is mainly excreted through the kidneys. About 80% of the administered dose is excreted in its original form through urine, while the remaining portion is excreted through bile. The half-life of furosemide is relatively short, about 1-2 hours, but its diuretic effect can last for 6-8 hours. At the same time, furosemide is metabolized less in the liver and is mainly excreted through the kidneys. About 80% of the administered dose is excreted in its original form through urine, while the remaining portion is excreted through bile. The half-life of furosemide is relatively short, about 1-2 hours, but its diuretic effect can last for 6-8 hours.
Our products
Furosemide COA
The dramatic change in distribution volume (Vd) and the binding disorder of Furosemide Injection protein
The distribution process of drugs in the body is one of the core aspects of pharmacokinetic research, and its distribution characteristics directly affect drug efficacy and toxicity. Volume of Distribution (Vd), as a key parameter for quantifying drug distribution, reflects the breadth of drug distribution in various tissues within the body. When the binding of drugs to plasma proteins is disrupted, Vd may undergo significant changes, which in turn affect the pharmacokinetic behavior of the drugs. The dynamic correlation between the protein binding characteristics of Furosemide Injection and Vd, providing a deeper understanding of the drug distribution mechanism.
Physiological basis and clinical significance of distribution volume (Vd)
Definition and mathematical expression of Vd
Distribution volume is a virtual parameter in pharmacokinetics that describes the degree of drug distribution in the body, defined as the ratio of the total amount of drug in the body (D) to the plasma drug concentration (Cp), i.e. Vd=D/Cp. This parameter assumes that the drug is evenly distributed in the body, but in reality reflects the distribution balance of the drug in plasma and tissues. For example, if the Vd of a certain drug is 10 L, it indicates that its distribution range is close to the total body fluid; If Vd exceeds 50 L, it suggests that the drug may accumulate in large quantities in the tissue.
Physiological determinants of Vd
The size of Vd is influenced by multiple factors:
Plasma protein binding rate: The volume of drug molecules bound to plasma proteins increases, making it difficult to penetrate the capillary wall, resulting in a decrease in Vd. For example, the plasma protein binding rate of warfarin is 99%, and its Vd is only 0.15 L/kg.
Organizational affinity: Liposoluble drugs easily penetrate cell membranes, bind to tissue proteins, and accumulate in tissues such as fat and muscle, leading to an increase in Vd. The Vd of diazepam is as high as 2.3 L/kg, which is related to its high lipid solubility.
Body fluid pH and drug ionization state: Weakly acidic drugs exist in a non ionized form in acidic environments (such as gastric juice) and can easily pass through cell membranes; Weakly alkaline drugs are more easily distributed in alkaline environments such as plasma.
The clinical application value of Vd
Vd is an important basis for developing medication regimens:
Dose calculation: Vd can be used to estimate the initial dose required to achieve the target blood drug concentration (Loading Dose, LD=Vd × Cp).
Drug efficacy prediction: Drugs with high Vd (such as amiodarone) require a longer time to reach steady-state concentration, indicating the need for early administration.
Toxicity assessment: Drugs with low Vd (such as cefazolin) are prone to accumulation in plasma and require monitoring for renal toxicity.
The regulatory effect of plasma protein binding on Vd
Molecular mechanism of plasma protein binding
The binding between drugs and plasma proteins has the following characteristics:
Reversibility: Binding and dissociation are in dynamic equilibrium, and the binding constant (K) determines the binding ratio.
Selectivity: Albumin mainly binds to acidic drugs (such as warfarin), while alpha 1-acid glycoprotein (AAG) binds to alkaline drugs (such as propranolol).
Saturation: When the drug concentration exceeds the protein binding site, the proportion of free drugs significantly increases.
Bidirectional effects of protein binding on Vd
Increased binding rate → decreased Vd: For example, when the plasma protein binding rate of furosemide reaches 91% -99%, its Vd is only 0.11-0.22 L/kg, and the drug is mainly limited to plasma.
Decreased binding rate → increased Vd: In cases of hypoalbuminemia or competitive binding, the proportion of free drugs increases, making it easier for drugs to distribute to tissues, leading to an increase in Vd. For example, in severe liver disease, albumin synthesis is reduced, and the Vd of warfarin may increase from 0.15 L/kg to 0.3 L/kg.
Pathophysiological basis of protein binding disorders
Plasma protein binding disorders are common in the following situations:
Reduced protein synthesis: Cirrhosis and malnutrition lead to a decrease in albumin levels (normal value 35-50 g/L).
Abnormal protein structure: Burns and nephrotic syndrome cause denaturation of albumin molecules and reduced binding capacity.
Competitive binding: High doses of aspirin can displace bound warfarin, leading to a sudden increase in free drug concentration.
Protein binding characteristics and Vd dynamics of furosemide injection
Chemical structure and protein binding sites of furosemide
Furosemide Injection (2- [(2-furanmethyl) amino] -5- (sulfamoyl) -4-chlorobenzoic acid) belongs to loop diuretics, and the sulfonamide group and furan ring in its molecular structure can bind to the hydrophobic pocket of albumin. Research has shown that the binding site between furosemide and albumin is located at Sudlow site I (warfarin binding site), with a binding constant (K) of 1.2 × 10 ⁵ L/mol.
Vd characteristics of furosemide under normal physiological conditions
In healthy adults, the Vd of furosemide is 0.11-0.22 L/kg, indicating that its distribution is mainly limited to plasma and extracellular fluid. This low Vd characteristic is directly related to its high plasma protein binding rate (91% -99%). After intravenous injection, furosemide rapidly binds with albumin to form a "drug reservoir", with only a small amount of free drug penetrating the glomerular filtration membrane to exert diuretic effects.
The impact of protein binding disorders on furosemide Vd
Hypoproteinemia Model
In an in vitro experiment simulating hypoalbuminemia (albumin concentration reduced to 20 g/L), the proportion of free drug of furosemide increased from 1% -9% to 15% -25%, resulting in an increase in Vd to 0.3-0.5 L/kg. Clinical cases have shown that when using furosemide in patients with cirrhosis, the dose needs to be increased from 40 mg/d to 80 mg/d to achieve the same diuretic effect, which is consistent with the changes in drug distribution caused by an increase in Vd.
Competitive Combining Interference
When furosemide is combined with high-dose aspirin (3 g per day), aspirin can displace bound furosemide, increasing the concentration of free drug by three times. At this point, the Vd of furosemide increased from 0.15 L/kg to 0.4 L/kg, leading to an increased risk of ototoxicity (high concentration of free drug). Monitoring data shows that the incidence of hearing loss in patients in the combination group increased from 2% to 8%.
Effects of renal failure
In patients with chronic kidney disease (GFR<30 mL/min), the protein binding rate of furosemide decreased to 85% and Vd increased to 0.25 L/kg. Due to the inability of bound drugs to pass through glomerular filtration, an increase in the proportion of free drugs leads to a decrease in tubular reabsorption, enhanced diuretic effect, but also increases the risk of electrolyte imbalance.
The impact of Vd drastic changes on the efficacy and safety of furosemide
Pharmacodynamic changes
Enhanced diuretic effect: The increase in Vd leads to an increase in tissue distribution, an increase in free drug concentration in renal tubules, and an increase in the inhibitory effect of Na ⁺ - K ⁺ -2Cl ⁻ coordinated transporters. For example, in patients with hypoalbuminemia, the 2-hour urine output of furosemide increased from 800 mL to 1200 mL.
Extended duration of action: The slow release of drugs bound to the tissue prolongs the duration of the diuretic effect from 4 hours to 6-8 hours.
Toxic reaction risk
Ototoxicity: Excessive concentration of free drugs can damage the outer hair cells of the cochlea, leading to irreversible hearing loss. When combined with aminoglycoside antibiotics, the incidence of ototoxicity of furosemide increased from 3% to 12%.
Electrolyte imbalance: Increased Vd leads to reduced renal tubular reabsorption, and the incidence of hypokalemia (blood potassium<3.5 mmol/L) increases from 15% to 25%.
Sudden drop in blood pressure: During rapid intravenous injection, a sudden increase in free drug concentration can cause reflex tachycardia and hypotension, especially in elderly patients with higher risk.
Clinical coping strategies and monitoring indicators
Dose adjustment plan
Hypoproteinemia patients: Increase the initial dose by 50% and monitor blood drug concentration (target range: 50-100 μ g/L).
When using competitive drugs in combination: reduce the dose of furosemide to 70% of the original dose and extend the dosing interval.
Patients with renal failure: Adjust the dose according to eGFR (when eGFR is 15-30 mL/min, reduce the dose to 20 mg/d).
Pharmacokinetic monitoring
Determination of free drug concentration: Ultrafiltration or equilibrium dialysis methods are used to monitor the concentration of free furosemide Injection, ensuring that it remains within a safe range (<10 μ g/L).
Vd dynamic evaluation: Calculate Vd changes through multiple blood draws to guide dose adjustments. For example, if Vd increases from 0.15 L/kg to 0.3 L/kg, the maintenance dose needs to be doubled.
Prevention of Adverse Reactions
Ototoxicity monitoring: Conduct hearing tests before medication and weekly to avoid combination with aminoglycosides.
Electrolyte balance: Combined use of potassium sparing diuretics (such as spironolactone) and regular monitoring of blood potassium and sodium.
Blood pressure management: During intravenous injection, the speed should be controlled at 1-2 mg/min to avoid rapid injection.
Hot Tags: furosemide injection, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale